Pfizer also has experienced multiple setbacks in its attempts to develop ... Nurtec ODT for migraine and Xtandi for prostate cancer. Adjusted earnings for 2024 will be $2.75 to $2.95 a share ...

In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

On the regulatory front this year, a Pfizer spokesperson said the company anticipates three regulatory decisions in prostate cancer, colorectal cancer and non-Hodgkin lymphoma, as well as seven Phase ...

compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. Also Read: Pfizer ...

cervical and prostate cancers. “At Pfizer, we partner across the oncology community to meet the needs of people with cancer and help everyone have access to quality cancer care,” said Jeffrey ...